Orexo Logo

Orexo

Develops pharmaceuticals & digital health for opioid use disorder in the US market.

ORX | ST

Overview

Corporate Details

ISIN(s):
SE0000736415 (+2 more)
LEI:
549300LJ5CCWDPTK9Z08
Country:
Sweden
Address:
Box 303, 751 05 UPPSALA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orexo is an international, commercial-stage pharmaceutical company specializing in the development of improved pharmaceuticals based on proprietary drug delivery technologies. With a 30-year history, the company creates innovative treatment solutions for significant medical needs. A primary focus for Orexo is the US market, where it commercializes drugs and digital mental health programs for patients suffering from opioid use disorder (OUD) and adjacent diseases. Through its robust product pipeline, Orexo is committed to addressing major public health challenges, including the opioid crisis.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 08:00
Quarterly Report
Swedish 4.8 MB
2025-10-23 08:00
Quarterly Report
English 4.8 MB
2025-10-17 08:00
Board/Management Information
Orexo:s valberedning inför årsstämman 2026
Swedish 78.0 KB
2025-10-17 08:00
Board/Management Information
Orexo´s Nomination Committee for the Annual General Meeting 2026
English 77.7 KB
2025-10-06 15:35
Major Shareholding Notification
Swedish 9.8 KB
2025-09-29 20:30
Regulatory News Service
Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership
English 86.4 KB
2025-09-29 20:30
Regulatory News Service
Orexo US får SEK 75 miljoner från BARDA för utvecklingssamarbete kring OX390 mo…
Swedish 88.2 KB
2025-07-16 08:00
Interim Report
Swedish 6.7 MB
2025-07-16 08:00
Interim Report
English 6.6 MB
2025-06-30 17:30
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Orexo
Swedish 76.3 KB
2025-06-30 17:30
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Orexo
English 76.6 KB
2025-06-25 11:38
Major Shareholding Notification
Swedish 9.8 KB
2025-06-19 16:40
Major Shareholding Notification
Swedish 9.9 KB
2025-06-18 18:00
Share Issue/Capital Change
Emission och återköp av C-aktier
Swedish 166.4 KB
2025-06-18 18:00
Share Issue/Capital Change
Issue and repurchase of class C shares
English 168.1 KB

Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orexo

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orexo via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-11 Nikolaj Arrild Sørensen Other Buy 2,460 35,178.00 SEK
2025-04-04 Nikolaj Arrild Sørensen Other Buy 3,500 47,530.00 SEK
2024-03-26 Fredrik Järrsten Other Buy 3,000 44,040.00 SEK
2023-11-24 Charlotte Vithlani Hansson Other Buy 3,000 44,640.00 SEK
2023-11-08 Fredrik Järrsten Other Buy 1,500 23,715.00 SEK
2023-02-24 Nikolaj Arrild Sørensen Other Buy 11,500 188,945.00 SEK
2023-01-27 Fredrik Järrsten Other Buy 4,500 79,695.00 SEK
2022-07-26 Michael Matly Other Buy 2,820 60,777.77 SEK
2022-07-21 Charlotte Vithlani Hansson Other Buy 3,000 61,500.00 SEK
2022-07-15 James Noble Other Buy 18,500 394,252.80 SEK

Peer Companies

Company Country Ticker View
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea 233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875

Talk to a Data Expert

Have a question? We'll get back to you promptly.